P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
ECCO'20 Vienna
2020
P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study
ECCO'20 Vienna
2020
P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease
ECCO'20 Vienna
2020
P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
ECCO'20 Vienna
2020
P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience
ECCO'20 Vienna
2020
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
ECCO'20 Vienna
2020
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
ECCO'20 Vienna
2020
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
ECCO'20 Vienna
2020
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
ECCO'20 Vienna
2020
P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study
ECCO'20 Vienna
2020
P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
ECCO'20 Vienna
2020
P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease
ECCO'20 Vienna
2020
P618 Post-operative Crohn’s disease patients undergoing colonoscopy require significantly more analgesia and sedation compared with a non-IBD population
ECCO'20 Vienna
2020
P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study
ECCO'20 Vienna
2020
P620 Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
ECCO'20 Vienna
2020